Conflicts of interest
Neeltje Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim and Ellipses Pharma and also received research grants for the institute from AB Science, Abbvie, Actuate Therapeutics, ADCtherapeutics, Amgen, Array, Ascendis Pharma, Astex, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Cresecendo, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead, GlaxoSmithKline, Incyte, InteRNA, Janssen/Johnson&Johnson, Kinate, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho, (outside the submitted work), and Takeda. Vickie Lu and Xiaofei Zhou are employees of Takeda. John Redman was a consultant to Takeda and served as the Global Clinical Leader during the TAK-931 program. Melinda Pruis and Carla van Herpen declare no potential conflicts of interest.